Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hypoallergenic Bet v 1 derivative
- Development stage
- Unknown
- Lead developer
- Allergopharma
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intranasal, Sublingual
01
Overview
Recombinant hypoallergenic Bet v 1 derivatives are genetically engineered proteins based on the major birch pollen allergen Bet v 1, produced to reduce their IgE-binding capacity while retaining T-cell immunogenicity. These derivatives—including folding variants (rBet v 1-FV), trimeric forms, and fragments—are designed as safer and effective agents for allergen-specific immunotherapy (AIT) of birch pollen allergy. By modifying the native Bet v 1 sequence or structure, these recombinant derivatives minimize anaphylactic activity while still eliciting immune responses that lead to tolerance or blocking antibody (IgG) production. Multiple clinical trials have shown efficacy in reducing allergic rhinoconjunctivitis symptoms and induction of immune tolerance with an improved safety profile compared to natural extract vaccines. Some derivatives are administered subcutaneously or intranasally, and others are evaluated for sublingual use[1][3][4][6][7].
- Other names
- recombinant hypoallergenic Bet v 1 folding variantrBet v 1-FVhypoallergenic Bet v 1 trimerrecombinant Bet v 1 fragmentshypoallergenic Bet v 1 derivative
02
Targets
Bet v 1-sIgE (Bet v 1-specific IgE)Bet v 1-specific T-cell receptor
Beyond the preview
Go deeper on recombinant hypoallergenic Bet v 1 derivative.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hypoallergenic Bet v 1 derivative.